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ABSTRACT
Objective There is emerging evidence that the pancreas 
may be a target organ of SARS- CoV-2 infection. This aim 
of this study was to investigate the outcome of patients 
with acute pancreatitis (AP) and coexistent SARS- CoV-2 
infection.
Design A prospective international multicentre cohort 
study including consecutive patients admitted with AP 
during the current pandemic was undertaken. Primary 
outcome measure was severity of AP. Secondary outcome 
measures were aetiology of AP, intensive care unit (ICU) 
admission, length of hospital stay, local complications, 
acute respiratory distress syndrome (ARDS), persistent 
organ failure and 30- day mortality. Multilevel logistic 
regression was used to compare the two groups.
Results 1777 patients with AP were included during the 
study period from 1 March to 23 July 2020. 149 patients 
(8.3%) had concomitant SARS- CoV-2 infection. Overall, 
SARS- CoV-2- positive patients were older male patients 
and more likely to develop severe AP and ARDS (p<0.001). 
Unadjusted analysis showed that SARS- CoV-2- positive 
patients with AP were more likely to require ICU admission 
(OR 5.21, p<0.001), local complications (OR 2.91, p<0.001), 
persistent organ failure (OR 7.32, p<0.001), prolonged 
hospital stay (OR 1.89, p<0.001) and a higher 30- day 
mortality (OR 6.56, p<0.001). Adjusted analysis showed 
length of stay (OR 1.32, p<0.001), persistent organ failure 
(OR 2.77, p<0.003) and 30- day mortality (OR 2.41, p<0.04) 
were significantly higher in SARS- CoV-2 co- infection.
Conclusion Patients with AP and coexistent SARS- CoV-2 
infection are at increased risk of severe AP, worse clinical 
outcomes, prolonged length of hospital stay and high 30- 
day mortality.
INTRODUCTION
Respiratory complications due to SARS- CoV-2 infec-
tion are the most commonly reported sequelae and 
the predominant cause of significant morbidity and 
mortality.1 However extrapulmonary symptoms 
and presentations have also been described with 
Significance of this study
What is already known on this subject?
 ► Emerging data suggest that the pancreas could 
be target organ for SARS- CoV-2 infection with 
increase in severity of pancreatitis.
 ► However, there is limited data on the clinical 
outcomes of patients with coexistent SARS- 
CoV-2 and acute pancreatitis (AP).
What are the new findings?
 ► Patients with AP and coexistent SARS- CoV-2 
have a significantly high 30- day inpatient 
mortality.
 ► These patients also have significantly worse 
clinical outcomes including increased severity 
of pancreatitis, length of stay and organ failure.
How might it impact on clinical practice in the 
foreseeable future?
 ► Data from the largest international multicentre 
study will enable clinicians to better 
prognosticate for patients with concomitant AP 
and SARS- CoV-2 infection, optimise resource 
allocation and target treatment options.
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GI symptoms frequently reported as presenting symptoms.2–4 
Emerging data suggest that the GI tract and pancreas are target 
organs of SARS- CoV-2 because ACE2 receptor is expressed in 
the GI tract including pancreas acinar and islet cells.5–7 This is 
supported by several published reports of AP in patients with 
SARS- CoV-2 infection.8–16 It has also been postulated that infec-
tion leads to increased expression and distribution of ACE2, partic-
ularly on the pancreatic islet cell, increasing the risk of pancreatic 
injury and hyperglycaemic.7 It is however unknown if SARS- CoV-2 
infection causes pancreatic injury and acute pancreatitis or cause 
an aggravated inflammatory response, and increased risk of organ 
failure and pancreatic complications leading to increased patient 
morbidity and mortality.17 The published evidence to date is 
largely from small case series and reports, which is insufficient to 
answer these questions.
This study reports the results of a multicentre international 
collaborative project to investigate the aetiology, clinical trajectory 
and outcomes in consecutive patients admitted with AP during the 
current SARS- CoV-2 pandemic.
METHODS
Study design, ethics approval and protocol
This was an international prospective multicentre collaborative 
cohort study of consecutive patients admitted with AP during 
the current SARS- CoV-2 pandemic.
Data were collected online in real time and stored on a secure 
data server running the Research Electronic Data Capture 
(REDCap) database. The database was held and monitored at 
the Newcastle Joint Research Office. No patient identifiable 
information was entered.
No patients were involved in setting the research question or 
the outcome measures, nor were they involved in developing 
plans for design or implementation of the study. No patients 
were asked to advice on interpretation or writing up of results. 
We plan to disseminate the results of the research to the relevant 
patient community.
Participating centres
The study was initiated and developed at the Freeman Hospital, 
Newcastle upon Tyne, UK. All hospitals admitting patients with 
acute pancreatitis in the UK and other global pancreatic units 
were eligible for the study and were invited to input their data 
on REDCap. Enrolment of consecutive patients commenced 
from the start of the SARS- CoV-2 pandemic in the respective 
hospitals.
Patients and procedures
Consecutive adult patients (18 years and over) admitted with AP 
during the SARS- CoV-2 pandemic were included in the study. 
The recruitment period was between 1 March 2020 and 23 July 
2020. All patients who had clinical symptoms consistent with 
SARS- CoV-2 or who were confirmed to have SARS- CoV-2 infec-
tion (by quantitative reverse transcription PCR (RT- PCR) and/
or positive imaging by CT thorax in the first 72 hours18 within 
admission) were all included. To avoid duplication of data, units 
were advised to inform us about patients who were being trans-
ferred to a regional tertiary care hospital for specialist input.
Definitions
SARS- CoV-2 infection was defined as a positive swab, positive 
CT thorax or a clinical diagnosis of symptomatic SARS- CoV-2 
in patients for whom a swab test and CT scan were unavailable. 
The rationale behind this methodology was the fact that during 
the initial stages of the current pandemic the swab test had a 
high false negative rate ~30% and some patients globally were 
diagnosed based on clinical symptoms and findings on cross- 
sectional imaging.
WHO case definitions were employed to further classify 
patients into confirmed SARS- CoV-2 case, probable SARS- CoV-2 
case and suspected SARS- CoV-2 case.19
Idiopathic pancreatitis was defined as patients who have been 
investigated prior to this admission and no cause found for 
pancreatitis.
Pancreatitis of unknown aetiology was defined as patients 
who during this particular admission did not have a defined 
aetiology despite multiple investigations at the time of 
discharge/death.
Severity of AP was defined as per the revised Atlanta criteria20 
which included:
Mild acute pancreatitis
 ► No organ failure.
 ► No local or systemic complications.
Moderately severe acute pancreatitis
 ► Organ failure that resolves within 48 hours (transient organ 
failure).
 ► Local or systemic complications without persistent organ 
failure.
Severe acute pancreatitis
 ► Persistent organ failure (>48 hours).
 – Single or multiple organ failure.
The Eastern Cooperative Oncology Group (ECOG) score was 
used to describe the patient’s level of functioning in terms of 
their ability to care for themselves, daily activity and physical 
ability (walking, working and so on) and the scale runs from 0 
to 5.21
Data variables
Multiple variables were collected, including demographic data, 
aetiology of acute pancreatitis at discharge, blood parameters 
including amylase on admission, serum bilirubin on admission, 
serum ferritin, lymphocyte count, D- dimer levels, C reactive 
protein, presenting symptoms, severity of AP (based on the 
revised Atlanta criteria), premorbid ECOG score, endoscopic or 
surgical interventions for drainage of pancreatic pseudocyst or 
walled off necrosis and 30- day mortality. In addition, duration 
of ICU stay and length of hospital stay were recorded (online 
supplemental file 1).
Outcome measures
The primary outcome measure was the severity of AP based 
on the revised Atlanta criteria. Secondary outcome measures 
included aetiology of AP, admission to intensive care unit and 
length of hospital stay, development of acute pancreatic fluid 
collections, pancreatic necrosis, pseudoaneursyms, pancreatic 
ascites, pancreaticopleural fistula, mesenteric- portal vein throm-
bosis, overall local complications, persistent organ failure and 
30- day mortality.
A further comparative analysis of baseline characteristics and 
outcomes of patients with SARS- CoV-2 infection and unknown 
aetiology of AP to those with known aetiology of AP was 
undertaken.
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Statistical analysis
To allow for the clustering of patients within different centres, 
all analyses were performed using multilevel regression methods. 
Two- level models were used with patients nested within centres.
Initially, the baseline/demographic characteristics of SARS- 
CoV-2- positive SARS- CoV-2- negative patients were compared. 
Continuous variables were analysed using multilevel linear 
regression, with variables found to have a positively skewed 
distribution analysed on the log scale. Multilevel logistic regres-
sion was used to compare the binary factors between the two 
groups, while multilevel ordinal logistic regression was preferred 
for those variables measured on an ordinal scale.
Subsequently, patient outcomes were compared between 
groups. Two analyses were performed for each outcome. 
Initially, a raw, unadjusted, comparison between groups was 
made. A second analysis compared the groups after adjusting for 
baseline/demographic factors found to show some evidence of a 
difference between the groups (all factors with p value of <0.2, 
providing that they were measured on the majority of patients). 
The SARS- CoV-2- positive SARS- CoV-2- negative groups were 
compared without considering any potential bias for: age, sex, 
smoking status, alcohol aetiology, idiopathic aetiology, unknown 
aetiology, other aetiology, ECOG and revised Atlanta criteria. 
Multilevel logistic regression was used for all binary outcomes. 
Multilevel linear regression was used for length of stay, which was 
analysed on the log scale due to the positively skewed distribu-
tion. Additional analyses compared the characteristics of positive 
patients with and without an unknown aetiology. Comparisons 
were again made using multilevel logistic regression.
A series of sensitivity analyses were performed using multiple 
imputation methods to impute missing data values for the base-
line/demographic factors and key outcomes (online supple-
mental file 2).
RESULTS
Over the study period, 1777 patients with AP were included in 
the REDCap database with last date for data entry on 23 July 
2020. Countries with contributing centres included England, 
Wales, Scotland, Northern Ireland, Malta, Italy, Pakistan, Turkey 
and Lithuania (online supplemental file 3).
One hundred forty- nine patients (8.3 %) developed concomi-
tant AP and SARS- CoV-2 infection.
Symptoms and diagnosis of SARS-CoV-2 infections
The predominant symptoms, apart from abdominal pain, in 
those diagnosed with a swab alone were fever in 9.4%, shortness 
of breath in 6.6% and cough in 4.7%. In all those with a clinical 
suspicion of infection, patients had fever in 13.6%, shortness of 
breath in 27.3% and cough in 22.7% of cases; 2.7% of patients 
presented with no abdominal pain, and rather only fever, short-
ness of breath or a cough.
Based on WHO case definitions, 118/149 (79%) of 
patients were confirmed cases with laboratory confirmation 
of SARS- CoV-2 testing on a positive swab; 16/149 (10.7%) of 
patients were classed as probable cases based on clinical criteria 
and suspicious chest imaging showing findings suggestive of 
SARS- CoV-2 infection. A further 15/149 (10%) patients were 
classed as suspicious cases based on clinical criteria alone.
Among the 118 patients with infection confirmed on a positive 
swab, 56 (56/118, 47.4%) patients had a positive swab on the 
day of admission, a further 31 (31/118, 26.2%) patients within 
72 hours of admission, 14 (14/118, 11.8%) patients between 
4 and 14 days of admission and 15 patients (15/118, 12.7%) 
14–90 days of admission.
Two patients had a positive swab in the community before 
hospital admission. Overall, 87% (88/101) of patients with a 
positive swab within 14 days of admission had hyperamylasaemia 
and abdominal pain suggestive of concomitant SARS- CoV-2 
infection and acute pancreatitis.
In the group of patients who had confirmed diagnosis of 
SARS- CoV-2 with a known aetiology (91/112, 81%), 2 patients 
had a positive swab (2/91, 2.2%) prior to admission, 44 patients 
(44/91, 48.3%) had a positive swab on the day of admission, 20 
patients (20/91, 22%) within 72 hours of admission, 13 patients 
(13/91, 14.3%) between 4 and 14 days of admission and 12 
patients (12/91, 13.2%) after 14 days from admission. Overall, 
84% of patients in the known aetiology group had a positive 
swab within 14 days of admission suggestive of concomitant 
SARS- CoV-2 infection in addition to an underlying aetiology 
to pancreatitis; 43/91 (47%) patients in this group developed 
moderate- to- severe or severe pancreatitis.
Hyperamylasaemia was noted at admission in 47/56 patients 
with positive swab on the day of admission, in 28/31 patients 
with a positive swab with 72 hours and in 13/14 patients with 
a positive swab between 4 and 14 days. Overall, 87% (88/101) 
of patients with a positive swab within 14 days of admission had 
hyperamylasaemia and abdominal pain.
Baseline characteristics of SARS-CoV-2-negative and SARS-
CoV-2-positive patients with AP
The demographic details are shown in table 1.
There were 294 patients with missing data on one or more 
of the baseline factors that were excluded from these analysis 
(255 SARS- CoV-2- negative patients, 39 SARS- CoV-2- positive 
patients). This amounted to 26.2% loss in the SARS- CoV-2- 
positive cohort and 15.6% in the SARS- CoV-2- negative cohort.
Gallstones were the most common aetiology of AP in both 
groups. SARS- CoV-2- positive patients were found to be older 
by approximately 5 years. The positive group also had a higher 
proportion of males when compared with the negative group. 
There was no significant difference in the ethnicity of the groups.
The number of patients with an alcohol aetiology was signifi-
cantly higher in the SARS- CoV-2- negative group (26.7% vs 
18.8%, p=0.04). The number of patients with an unknown 
aetiology was more common in the SARS- CoV-2- positive group 
(24.8% vs 19.4%), but this difference was not statistically signif-
icant (p=0.08).
The ECOG score was significantly higher in the SARS- CoV-2- 
positive patients, with 15% having a score of 3 or 4, compared 
with only 4% of SARS- CoV-2- negative patients (p<0.001). 
There was no significant difference in liver steatosis or body 
mass index between groups.
The severity of AP was significantly worse in SARS- CoV-
2- positive patients, with over 22.6% of patients in this group 
developing severe pancreatitis, compared with only 6.3% of 
SARS- CoV-2- negative patients (p<0.001). The occurrence of 
ARDS was also significantly higher in the SARS- CoV-2- positive 
group (13.6% vs 4%, p<0.001).
Necrosectomy was more likely to be performed in the SARS- 
CoV-2- positive patients, occurring in over 5%, compared with 
1% in the SARS- CoV-2- negative patients (p<0.001). Conversely, 
an index cholecystectomy was less frequent in the SARS- CoV-2- 
positive patients (p<0.02).
Furthermore, 49% (43/88) of patients with a posi-
tive SARS- CoV-2 swab within 14 days of admission and 
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hyperamylasaemia developed moderate- to- severe or severe 
pancreatitis.
Specific data on fluid resuscitation protocols were not avail-
able however, the fluid resuscitation for patients with acute 
pancreatitis in the UK is based on National Institute for Health 
and Care Excellence guidance on resuscitation of acutely ill 
patients.22
Outcomes for SARS-CoV-2-positive SARS-CoV-2-negative 
patients with AP
The SARS- CoV-2- positive SARS- CoV-2- negative groups were 
compared without considering any potential confounding 
factors, and then repeated with adjustments for factors found 
to show some evidence of a difference between positive and 
negative patients. The factors included as part of the adjusted 
analysis were age, sex, smoking status, alcohol status, idiopathic 
aetiology and unknown aetiology at discharge, ECOG status and 
severity of AP.
There were 294 patients with missing data on one or more 
of the baseline factors that were excluded from these analysis 
(255 SARS- CoV-2- negative patients, 39 SARS- CoV-2- positive 
patients). This left a total of 1483 patients for analysis (1373 
negative, 110 positive) (table 2).
Table 1 Comparison of the baseline characteristics of all SARS- CoV-2- positive SARS- CoV-2- negative patients
Variable Category
SARS- CoV-2 negative SARS- CoV-2 positive
P valueN Summary N Summary
Number of patients*   1628 – 149 –
Age – 1618 54.5±18.1 147 59.9±17.2 0.001
Sex Female 1620 786 (48.5%) 148 55 (37.2%) 0.009
  Male 834 (51.5%) 93 (62.8%)
Ethnicity White 1358 1202 (88.5%) 122 104 (85.3%) 0.76
  Asian 92 (6.8%) 11 (9.0%)
  Black 19 (1.4%) 2 (1.6%)
  Mixed/Other 45 (3.3%) 5 (4.1%)
Smoker No 1517 1043 (68.7%) 132 100 (75.8%) 0.05
  Yes 474 (31.3%) 32 (24.2%)
Aetiology Gallstones 1628 696 (42.8%) 149 60 (40.3%) 0.37
(dis)† Alcohol 434 (26.7%) 28 (18.8%) 0.04
  Idiopathic 93 (5.7%) 13 (8.7%) 0.14
  Hereditary 4 (0.3%) 0 (0.0%) ‡
  Post- ERCP 43 (2.6%) 3 (2.0%) 0.64
  Post- EUS 2 (0.1%) 0 (0.0%) ‡
  Steroid 8 (0.5%) 1 (0.7%) 0.77
  Hypercalcaemia 2 (0.1%) 0 (0.0%) ‡
  Hyperlipidaemia 49 (3.0%) 6 (4.0%) 0.47
  Unknown 315 (19.4%) 37 (24.8%) 0.08
  Other 5 (0.3%) 2 (1.3%) 0.11
Premorbid 0 1534 945 (61.6%) 125 58 (46.4%) <0.001
ECOG status 1 373 (24.3%) 31 (24.8%)
  2 153 (10.0%) 17 (13.6%)
  3 or 4 63 (4.1%) 19 (15.2%)
Ferritin – 77 246 (106, 742) 20 910 (478, 1362) 0.001
LDH – 508 375 (242, 540) 52 370 (276, 610) 0.53
Revised Atlanta Mild 1600 1244 (77.7%) 146 71 (48.6%) <0.001
Criteria Moderate- to- severe 256 (16.0%) 42 (28.8%)
  Severe 100 (6.3%) 33 (22.6%)
ARDS No 1387 56 (96.0%) 140 121 (86.4%) <0.001
  Yes 56 (4.0%) 19 (13.6%)
Liver steatosis No 739 541 (73.2%) 62 48 (77.4%) 0.45
Yes 198 (26.8%) 14 (22.6%)
BMI – 845 27.4 (23.7, 32.1) 91 28.4 (24.5, 33.1) 0.41
Necrosectomy No 1605 1585 (98.7%) 145 137 (94.5%) <0.001
Yes 20 (1.3%) 8 (5.5%)
Index No 1551 1467 (94.6%) 145 144 (99.3%) 0.02
Cholecystectomy Yes 84 (5.4%) 1 (0.7%)
Summary statistics are mean±SD, median (p75–p25) or number (percentage). (*) Patients could have >1 aetiology so each aetiology considered as a separate variable.
*Includes all patients.
†Patients could have >1 aetiology so each aetiology considered as a separate variable.
‡Insufficient occurrences to enable a formal group comparison.
ARDS, acute respiratory distress syndrome; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.
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The overall 30- day mortality rate in the SARS- CoV-2- positive 
cohort was 14.7% compared with 2.6% in the SARS- CoV-2- 
negative group (p<0.04).
Unadjusted analyses of outcomes showed that patients with 
concomitant SARS- CoV-2 infection and AP were more likely to 
require ICU admission (OR 5.21, 95% CI 3.06 to 8.85), develop 
acute pancreatic fluid collections (OR 3.33, 95% CI 2.15 to 
5.16), pancreatic necrosis (OR 2.35, 95% CI 1.41 to 3.90), 
local complications (OR 2.91, 95% CI 1.89 to 4.49), persistent 
organ failure (OR7.32, 95% CI 4.48 to 12.0), prolonged length 
of hospital stay (OR 1.89, 95% CI 1.64 to 2.19) and increased 
30- day mortality (OR 6.56, 95% CI 3.44 to 12.5).
Potential confounding variables were then adjusted for some 
of the differences between the positive and negative groups. The 
30- day mortality was higher in the SARS- CoV-2- positive group 
with an OR of 2.4 (95% CI 3.44 to 12.5). The length of hospital 
stay (OR 1.32, 95% CI 3.44 to 12.5) and persistent organ failure 
(OR 2.77, 95% CI 1.43 to 5.39) were worse in the SARS- CoV-
2- positive group.
Respiratory failure was the predominant organ failure in the 
majority of SARS- CoV-2- positive patients. Thirty- one patients 
developed respiratory failure, seven patients a combination of 
renal, respiratory and cardiovascular failure, four patients renal, 
respiratory failure and cardiovascular failure, two patients renal 
and respiratory failure and two patients renal failure. In patients 
who died in the SARS- CoV-2- positive group, pulmonary 
complication secondary to SARS- CoV-2 infection was the cause 
of death.
We analysed portal vein thrombus rates in SARS- CoV-2- 
positive SARS- CoV-2- negative group and found no significant 
difference and these data. We have further reviewed the CT scan 
data and there were no reported instances of ischaemic damage 
especially in the intestine.
A further subgroup analysis of outcomes between specialist 
pancreatic centres and non- specialist centres was undertaken. 
Sixty- four patients were transferred to specialist units for further 
management. These only accounted for 3.6% of patients in the 
study group. Furthermore for the purpose of analysis, when 
comparing outcomes for specialist and non- specialist centres, 
these patients were considered to be in specialist centres. There 
was no significant difference in outcomes between the specialist 
and non- specialist centres for both SARS- CoV-2- positive SARS- 
CoV-2- negative patients (online supplemental file 4).
Comparison of outcomes between confirmed SARS-CoV-2 
swab-positive (true positives) patients and SARS-Cov-2 swab-
negative patients (true negatives)
A further subgroup analysis comparing confirmed SARS- CoV-2 
swab- positive (true positives) patients and SARS- Cov-2 swab- 
negative patients (true negatives) was undertaken. Among the 
1131/1777 (63.6%) patients tested, data on swab results were 
Table 2 Comparison of outcomes between SARS- CoV-2- positive SARS- CoV-2- negative patients
Outcome
COVID Unadjusted analysis* Adjusted analysis†
Status N n (%) OR (95% CI) P value N OR (95% CI) P value
ICU admission Negative 1367 100 (7.3%) 1 <0.001 1367 1 0.09
  Positive 110 27 (24.6%) 5.21 (3.06 to 8.85) 110 1.89 (0.91 to 3.95)
30- day mortality Negative 1328 34 (2.6%) 1 <0.001 1328 1 0.04
  Positive 102 15 (14.7%) 6.56 (3.44 to 12.5) 102 2.41 (1.02 to 5.71)
Length of hospital stay‡ Negative 1341 4 (3, 8) 1 <0.001 1341 1 <0.001
  Positive 101 9 (5, 17) 1.89 (1.64 to 2.19) 101 1.32 (1.16 to 1.50)
Pancreatic necrosis Negative 1188 177 (12.2%) 1 0.001 1188 1 0.48
(suspected or +ve) Positive 103 24 (23.3%) 2.35 (1.41 to 3.90) 103 0.79 (0.41 to 1.52)
Acute pancreatic fluid collections Negative 1190 253 (21.3%) 1 <0.001 1190 1 0.05
(suspected or +ve) Positive 103 47 (45.6%) 3.33 (2.15 to 5.16) 103 1.70 (1.00 to 2.88)
Pseudoaneurysms Negative 1185 12 (1.0%) 1 0.97 1185 1 0.27
(suspected or +ve) Positive 103 1 (1.0%) 0.96 (0.12 to 7.44) 103 0.30 (0.03 to 2.59)
Pancreato- pleural fistula Negative 1188 10 (0.8%) (§) 1188 (§)
(suspected or +ve) Positive 102 0 (0.0%) 102
Enteric fistula Negative 1185 10 (0.8%) 1 0.22 1185 1 0.99
(suspected or +ve) Positive 102 2 (2.0%) 2.61 (0.56 to 12.3) 102 0.99 (0.18 to 5.48)
Pancreatic ascites Negative 1187 86 (7.3%) 1 0.006 1187 1 0.47
(suspected or +ve) Positive 103 15 (14.6%) 2.45 (1.29 to 4.65) 103 1.33 (0.62 to 2.85)
Portal vein thrombus Negative 1180 35 (3.0%) 1 0.89 1180 1 0.19
(suspected or +ve) Positive 101 3 (3.0%) 1.09 (0.32 to 3.75) 101 0.40 (0.10 to 1.55)
Any local complication¶ Negative 1180 380 (26.1%) 1 <0.001 1180 1 0.22
Positive 101 50 (49.5%) 2.91 (1.89 to 4.49) 101 1.40 (0.81 to 2.40)
Persistent organ failure Negative 1338 73 (5.5%) 1 <0.001 1338 1 0.003
  Positive 144 37 (25.7%) 7.32 (4.48 to 12.0) 144 2.77 (1.43 to 5.39)
*Two hundred ninety- four patients with missing data on one or more of the baseline factors that were excluded from the analysis (255 SARS- CoV-2- negative patients, 39 SARS- 
CoV-2- positive patients); 1483 patients were included in the analysis (1373 SARS- CoV-2- negative patients, 110 SARS- CoV-2- positive patients).
†Adjusted for: age, sex, smoking status, alcohol aetiology, idiopathic aetiology, unknown aetiology, other aetiology, ECOG, Atlanta classification.
‡Summary statistics are: median (p75–p25). Group differences reported as: ratio (95% CI).
§Insufficient occurrences to enable a formal group comparison.
¶Defined as any of: acute pancreatic fluid collection, pseudoaneurysm, pancreatic pleural fistula, enteric fistula, pancreatic ascites or portal vein thrombus.
ECOG, Eastern Cooperative Oncology Group; ICU, intensive care unit.
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available for 1101 patients (61.9%); 983/1101 confirmed cases 
had a negative swab test and were considered as confirmed nega-
tive patients and 118/1101 confirmed cases had confirmed posi-
tive swab test and were considered as confirmed positive cases.
Of the 1101 confirmed patients, some patients were excluded 
from the analysis due to missing values for the baseline factors/
covariates. One hundred fifty- six patients were excluded from 
the negative group and 36 from the positive group. This left 909 
patients for analysis, 827 negative and 82 positive patients.
Comparisons of outcomes between the groups were made, 
and a summary of both the unadjusted and adjusted analyses are 
presented in online supplemental file 5.
The outcomes were again are comparable to the original 
outcomes including all patients. The outcomes again showed 
increased risk of persistent organ failure, increased hospital 
stay and 30- day mortality in confirmed SARS- CoV-2- positive 
patients (online supplemental file 5).
An additional sensitivity analyses was undertaken including 
only those patients without confirmed SARS- CoV-2 infection. 
Six hundred forty- five of the 1628 negative patients (39.2%) had 
no swab test result and were considered as unconfirmed negative 
patients. Thirty- one of the 149 positive patients (20.8%) had 
unconfirmed positive status based on the WHO classification. Of 
the 676 unconfirmed cases, some cases were excluded from the 
analysis due to missing values for the baseline factors/covariates. 
Ninety- nine were excluded from the negative group and three 
from the positive group. This left 574 patients for analysis, 546 
negative and 28 positive patients. The unadjusted analysis again 
showed the SARS- CoV-2 positive group is at increased risk of 
ICU admission, 30- day mortality, organ failure, increased local 
complications and prolonged hospital stay. The adjusted analysis 
showed a prolonged hospital stay (online supplemental file 6).
Outcome data of unknown aetiology in SARS-CoV-2-positive 
patients
A further subgroup analysis of patients with unknown aetiology 
of AP was undertaken in comparison to those with known aeti-
ology of AP. This analysis focused only on the SARS- CoV-2- 
positive patients (n=149). Of these, 37 (25%) had an unknown 
aetiology (at discharge), while the remaining 112 (75%) had a 
defined aetiology.
None of the outcome variables was different between the two 
different aetiology groups (p>0.05) (table 3).
DISCUSSION
This multicentre, international cohort study is the largest in the 
literature to study the impact of SARS- CoV-2 in patients presenting 
with AP. Patients with concomitant AP and SARS- CoV-2 tented 
to be older, male and with higher ECOG score. SARS- CoV-2- 
positive patients with AP were at a significantly increased risk 
of developing moderate- to- severe or severe AP, local complica-
tions, ARDS, persistent organ failure, prolonged ICU stay and 
high inpatient 30- day mortality. Of note, the 30- day mortality 
of 14.7% is significantly higher than in patients with AP without 
SARS- CoV-2 infection (2.6%).
At the outset of the SARS- CoV-2 pandemic, the symptoms of 
SARS- CoV-2 were considered predominantly respiratory with 
GI symptoms significantly less common.5 23–25 However, as the 
pandemic evolved and with accumulating evidence on various 
presentations of SARS- CoV-2 infection, the GI tract and pancreas 
were identified as potential target organs of SARS- CoV-2 on the 
basis of expression of ACE2, the major receptor of SARS- CoV-2, 
on the pancreatic islet cells.7 Furthermore, the rate of the severe/
critical SARS- CoV-2 disease was noted to be significantly higher 
in patients with GI symptoms.25 26 However, the impact of these 
observations on AP severity and clinical trajectory was unknown.
The first reported series of pancreatic injury from SARS- CoV-2 
was reported from China in January 2020 at the outset of the 
SARS- CoV-2 pandemic.1–3 Liu et al7 described a series of 121 
patients with SARS- CoV-2, of which 13 patients developed 
pancreatitis with the risk of developing pancreatitis being much 
higher in patients with severe SARS- CoV-2 infection. Wang 
et al4 described 138 patients with SARS- CoV-2 pneumonia 
and 9 patients developed pancreatic injury with more severe 
illness at admission. With the spread of the pandemic outside 
China, further cohort studies were reported from the USA and 
UK.14 16 Gubatan et al15 reported 102 patients with a history of 
pancreatitis and found 8 patients developed SARS- CoV-2 spec-
ulating that patients with previous history of pancreatitis may 
be susceptible to SARS- CoV-2 infection. Szatmary et al16 in a 
series of 35 patients with acute pancreatitis identified 5 patients 
with SARS- CoV-2 infection who were predominantly male, 
Table 3 Comparison of outcomes between known and unknown aetiology of pancreatitis in SARS- CoV-2- positive patients
Outcome
Known aetiology Unknown aetiology
OR (95% CI)† P valueN* n (%) N n (%)
ICU admission 111 20 (18.0%) 37 9 (7.3%) 1.49 (0.59 to 3.79) 0.40
30- day mortality 103 12 (11.7%) 35 6 (17.1%) 1.57 (0.54 to 4.56) 0.41
Length of stay‡ 100 8 (5, 16) 35 12 (5, 21) 1.26 (0.91 to 1.73) 0.16
Pancreatic necrosis 105 22 (21.0%) 34 9 (26.5%) 1.36 (0.55 to 3.32) 0.50
Acute pancreatic fluid collections 107 43 (40.2%) 34 17 (50.0%) 1.54 (0.68 to 3.50) 0.30
Pseudoaneurysm 107 1 (0.9%) 34 0 (0.0%) – §
Pancreato- pleural fistula 106 0 (0.0%) 33 0 (0.0%) – §
Enteric fistula 107 2 (1.9%) 32 0 (0.0%) – §
Pancreatic ascites 107 14 (13.1%) 34 6 (17.7%) 1.77 (0.50 to 6.22) 0.37
Portal vein thrombus 105 1 (1.0%) 34 2 (5.9%) 6.50 (0.57 to 74.0) 0.13
Any local complication¶ 105 47 (44.8%) 34 18 (52.9%) 1.41 (0.63 to 3.20) 0.41
Persistent organ failure 111 29 (26.1%) 36 15 (41.7%) 2.09 (0.88 to 4.95) 0.09
*Indicates the number of patients included in the analysis.
†ORs expressed as odds in unknown aetiology group relative to the odds in known aetiology group.
‡Summary statistics are: median (p75–p25). Group differences reported as: ratio (95% CI).
§Insufficient occurrences to enable a formal group comparison.
¶Defined as any of: acute pancreatic fluid collection, pseudoaneurysm, pancreatic pleural fistula, enteric fistula, pancreatic ascites or portal vein thrombus.
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overweight or obese with elevated triglycerides and glucose at 
admission with no apparent aetiology for the pancreatitis. The 
present study did not show a significant difference between the 
groups for severity of liver steatosis.
The present study has shown that patients with concomi-
tant SARS- CoV-2 and AP are at significantly increased risk of 
developing moderate- to- severe or severe AP. In addition, these 
patients also appear to be at a higher risk of developing local 
complications secondary to AP. These results therefore raise the 
important question of whether SARS- CoV-2 infection directly 
causes increased severity of AP. Recent published evidence on 
expression of ACE2 receptors suggests that messenger RNA level 
of ACE2 expression were noted to be higher in the pancreas than 
in the lung and ACE2 receptors are expressed both on endocrine 
and islet cells of the pancreas.27 This increased expression of ACE2 
receptors in the pancreas may increase viral load and worsen 
the clinical trajectory of AP, especially in the presence of severe 
SARS- CoV-2 infection.28 An exaggerated immune response with 
subsequent cytokine storm and endothelial damage may worsen 
the clinical trajectory similar to other pro- inflammatory condi-
tions with concomitant SARS- CoV-2 infection such as multi-
system inflammatory syndrome in children and adolescents.29–31 
Neutrophils play a significant role in innate response after acute 
pancreatitis through formation of neutrophil extracellular traps 
(NETs). NETs have been shown to worsen pancreatic inflam-
mation, and promoting pancreatic duct obstruction in patients 
with acute pancreatitis. Recent studies have shown increased 
concentrations NETs in plasma of patients with SARS- CoV-2 
infection and much higher concentration in patients with ARDS 
and respiratory failure. The generation of NETs by neutrophils 
can be triggered by viral infections and although their predom-
inant function is to trap viruses, virus- induced NETs can trigger 
inflammatory and immunological responses leading to exagger-
ated systematic inflammatory response.32 33
Furthermore, endothelial damage and severe endothelitis is 
frequent in SARS- CoV-2 infection,34 although further data are 
needed to determine whether marked prothrombotic changes 
seen in these patients are specific to SARS- CoV-2 infection or 
secondary to the cytokine storm. The thrombotic complications 
and abnormal coagulopathy reported in patients with severe 
SARS- CoV-2 may have further contributed to the worsening 
of acute pancreatitis. Autopsy data on pancreatic damage are 
not available as this was not the remit of the study, however 
given the published lung and intestine autopsy data in patients 
with SARS- CoV-2 infection has consistently shown presence 
of platelet–fibrin thrombi in small arterial vessels and coagu-
lopathy, it is highly likely similar changes are expected within 
the pancreas.33 The UK Randomised Evaluation of COVID-19 
Therapy (RECOVERY) Trial has shown the use of dexameth-
asone reduces death rate by a third of patients by suppressing 
the immune response further supporting the hypothesis of a 
hyper- immune response and tissue injury from SARS- CoV-2 
infection.35
The present series also identified a higher number of patients 
with SARS- CoV-2 infection having AP of unknown aetiology 
(24.8%). The absence of definite aetiology further raises ques-
tions regarding the potential role of SARS- CoV-2 inducing 
primary pancreatic damage or worsening the course of under-
lying AP. Viral- induced pancreatic damage is well studied and 
causes inflammation by acinar cell necrosis and damage early 
in the course of infection.36 In the present series, the majority 
of patients with concomitant AP and SARS- CoV-2 infection, 
especially in those with a SARS- CoV-2 infection conformed 
on a positive swab with 14 days of admission presented with 
abdominal pain and respiratory symptoms and hyperamyla-
saemia in support of the hypothesis that SARS- Cov-2 may cause 
pancreatic injury and pancreatitis. However, this association can 
only be substantiated by use of a pancreas organoid model to 
study the pancreas- specific effects of SARS- CoV-2.37
The mortality rate in the SARS- CoV-2- positive group is 
much higher (p<0.001) than published series reporting early 
mortality after acute AP.24 38 The increased mortality is most 
likely secondary to the fact that patients in the SARS- CoV-2- 
positive group were older patients with worse ECOG score with 
moderate- to- severe and severe AP, ARDS and persistent organ 
failure.
The present study has limitations. There are several partici-
pating centres in the UK and overseas with varied testing proto-
cols. During the early phase of the pandemic when routine 
testing was not available the diagnosis of SARS- CoV-2 was made 
using symptoms and CT criteria. However, this was the case only 
in a small number of patients with the majority of SARS- CoV-2 
infection confirmed on laboratory testing. The poor sensitivity 
of testing during the early phase of the pandemic means there 
may be a small fraction of patients who were presumed negative 
for SARS- CoV-2 infection included in the group of patients with 
acute pancreatitis with no SARS- CoV-2 infection. However, this 
study used several methods to make a diagnosis of SARS- CoV-2 
and therefore this number is likely to be small.
However, the study has several strengths. To the best of our 
knowledge, this is the largest international prospective cohort 
of patients with concomitant AP and SARS- CoV-2 infection 
reported to date. This has enabled a more detailed analysis to 
quantify the impact of SARS- CoV-2 infection on the course of 
AP. This is also the first study to highlight the significantly high 
inpatient morbidity and mortality within 30 days in the presence 
of SARS- CoV-2 infection and could potentially help target treat-
ments including dexamethasone or remdesevir.
In conclusion, patients presenting with concomitant 
SARS- CoV-2 infection and acute pancreatitis are at higher risk 
of developing severe AP with associated increased morbidity and 
mortality. These findings have implications for management of 
patients with acute pancreatitis during the current pandemic. 
If the infection continues to be prevalent without an effective 
treatment or vaccine, these data help clinicians to better prog-
nosticate for patients with concomitant AP and SARS- CoV-2 
infection and optimise resource allocation.
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Supplementary file 1 - Case report form (CRF) detailing data variables  
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Supplementary file 2 : Comparison of outcomes between confirmed SARS-CoV-2 Positive and 
Negative patients using imputed datasets 
 
 
Outcome COVID  Unadjusted Analysis (**) Adjusted Analysis (~) (***) 
 status N OR (95% CI) P-value N OR (95% CI) P-value 
        
ICU admission Negative 1628     1 <0.001 1628    1 0.11 
 Positive 149 3.63 (2.23, 5.90)  149 1.76 (0.89, 3.50)  
        
30-day mortality Negative 1628     1 <0.001 1628    1 0.02 
 Positive 149 4.94 (2.70, 9.03)  149 2.59 (1.17, 5.74)  
        
Length of hospital 
stay (*) 
Negative 1628     1 <0.001 1628    1 <0.001 
 Positive 149 1.76 (1.54, 2.00)  149 1.27 (1.12, 1.43)  
        
Necrosis Negative 1628     1 <0.001 1628    1 0.49 
(suspected or +ve) Positive 149 2.31 (1.46, 3.63)  149 0.80 (0.43, 1.49)  
        
Any local 
complication (#) 
Negative 1628     1 <0.001 1628     1 0.15 
 Positive 149 2.65 (1.83, 3.84)  149 1.41 (0.89, 2.24)  
        
Persistent organ 
failure 
Negative 1628     1 <0.001 1628    1 <0.001 
 Positive 149 6.26 (4.01, 9.80)  149 3.38 (1.81, 6.29)  
        
(~) Adjusted for: age, sex, smoking status, alcohol aetiology, idiopathic aetiology, unknown aetiology, other aetiology, ECOG, 
Atlanta classification. 
(*) Summary statistics are: Median [Inter-quartile range]. Group differences reported as: Ratio (95% CI) 
(#) Defined as any of: Collection, Pseudoaneurysm, Pancreatic Pleural Fistula, Enteric Fistula, Pancreatic Ascites, or Portal 
Vein Thrombus 
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Supplementary file 3 – List of participating units 
 
Specialist pancreatic centres Number of 
patients 
Non Specialist Pancreatic Centres Number of 
patients 
University Birmingham Hospitals 34 Brighton and Sussex University Hospitals NHS Trust 15 
University Hospitals Bristol and Weston NHS Foundation 
Trust 
30 Chesterfield Royal Hospital 13 
Addenbrookes, Cambridge University Hospitals 29 University Hospitals of Derby and Burton 59 
Coventry and Warwickshire Partnership NHS trust 45 Doncaster Royal Infirmary 53 
Edinburgh Royal Infirmary 71 NHS Dumfries and Galloway 31 
Greater Glasgow and Clyde NHS Trust 55 NHS Forth Valley 34 
Klaipeda University Hospital, Lithuania 18 Frimley - Frimley Park NHS Foundation Trust 7 
Leeds Teaching Hospitals NHS Trust 73 Frimley - Wexham Park NHS Foundation Trust 36 
Aintree University Hospital 65 Gloucestershire Hospitals NHS Foundation Trust 54 
Royal Liverpool and Broadgreen NHS Foundation Trust 26 Good Hope Hospital Birmingham 38 
Mater Dei Hospital, Malta 23 Aberdeen Royal Infirmary 9 
Manchester Royal Infirmary 28 Heartlands Hospital, Birmingham 29 
Newcastle upon Tyne Hospitals NHS Foundation Trust 82 Lewisham and Greenwich NHS Trust 47 
Nottingham University Hospitals 61 North Bristol NHS Trust 81 
University Hospitals Plymouth NHS Foundation Trust 25 Northampton General Hospital 40 
Royal Surrey County Hospital NHS Trust 23 Princess Alexandra Hospital 33 
Sapienza University Hospitals Rome 21 Royal Gwent Hospital 28 
Sheffield Teaching Hospital 65 South Tees Hospitals NHS Foundation Trust 34 
University Hospitals Southampton NHS Foundation Trust 50 South Warwickshire NHS Foundation Trust 4 
Swansea Bay University Health Board 44 Surrey and Sussex Healthcare NHS Trust 69 
Ziauddin Hospital, Pakistan 10 Taunton and Somerset NHS Foundation Trust 32 
Cardiff University Hospital of Wales 37 Tepecik Teaching and Research Hospital 12 
Guy's and St Thomas NHS Foundation Trust 5 Western Health and Social Care Trust 16 
  
Weston General Hospital 15 
  
Whittington Health NHS Trust 8 
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Supplementary file 4: Comparison of outcomes between SARS-CoV-2 Positive and Negative patients 
comparing specialist vs. non specialist pancreatic centres 
Outcome Centre COVID  Unadjusted Analysis (**) Adjusted Analysis (~) (***) 











           
ICU  Non- Negative 753 4.4% 0.18 1 <0.001 0.81    1 0.14 
admission specialist Positive 68 23.5%  7.19  
(3.58, 
14.4) 




           
 Specialist Negative 614 10.9%  1   0.002      1 0.33 
  Positive 42 26.2%  3.52 
(1.60, 
7.76) 




           
           
30-day  Non- Negative 728 2.3% 0.47 1 <0.001 0.78 1 0.07 
mortality specialist Positive 62 16.1%  8.04 
(3.51, 
18.4) 




           
 Specialist Negative 600 2.8%  1   0.003 0.78  1 0.30 
  Positive 40 12.5%  4.90 
(1.71, 
14.0) 




           
           
Length of 
hospital  
Non- Negative 736 4 [3, 7] 0.21 1 <0.001 0.36 1 <0.001 









           
 Specialist Negative 605 5 [3, 8]  1 <0.001  1 0.05 









           
           
Pancreatic 
Necrosis 
Non- Negative 623 9.6% 0.76 1   0.007 0.93 1 0.59 
 specialist Positive 62 21.0%  2.54 
(1.29, 
4.99) 




           
 Specialist Negative 565 15.0%  1 0.04  1 0.76 
  Positive 41 26.8%  2.16 
(1.03, 
4.55) 





























 specialist Positive 62 46.8%  4.05 
(2.29, 
7.16) 




           
 Specialist Negative 568 23.4%  1   0.007   1 0.50 
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  Positive 41 43.9%  2.56 
(1.30, 
5.05) 






          
 





















complication  specialist Positive 60 53.3%  3.74 
(2.12, 
6.57) 




(#)           
 Specialist Negative 567 28.0%  1 0.04  1 0.91 
  Positive 41 43.9%  2.06 
(1.05, 
4.05) 




           
Persistent 
organ failure 
Non- Negative 764 6.2% 0.64 1 <0.001 0.45 1 0.07 
 specialist Positive 60 35.0%  8.10 
(4.28, 
15.3) 




           
 Specialist Negative 574 4.5%  1 <0.001  1 0.01 
  Positive 84 19.1%  6.41 
(3.06, 
13.4) 




           
 
(~) Adjusted for: age, sex, smoking status, alcohol aetiology, idiopathic aetiology, unknown aetiology, other 
aetiology, ECOG, Atlanta classification, necrosectomy and cholecystectomy 
(*) Summary statistics are: Median [p75-p25]. Group differences reported as: Ratio (95% CI) 
(~) Adjusted for: age, sex, smoking status, alcohol aetiology, idiopathic aetiology, unknown aetiology, other 
aetiology, ECOG, Atlanta classification, necrosectomy and cholecystectomy 
(#) Defined as any of: Collection, Pseudoaneurysm, Pancreatic Pleural Fistula, Enteric Fistula, Pancreatic 
Ascites, or Portal Vein Thrombus 
(~) Adjusted for: age, sex, smoking status, alcohol aetiology, idiopathic aetiology, unknown aetiology, other 
aetiology, ECOG, Atlanta classification 
(**) (***) 920 patients were managed in specialist centers and 857 patients in non-specialist centers  
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Supplementary file 5 : Comparison of outcomes between swab confirmed 
  SARS-CoV-2 Positive and Negative patients 
 
Outcome COVID  Unadjusted Analysis Adjusted Analysis (~) 








         
ICU admission Negative 822 82 
(10.0%) 
  1 <0.001 822  1 0.47 




 82 1.38 (0.58, 
3.30) 
 
         
30-day 
mortality 
Negative 789 27 
(3.4%) 
  1 <0.001 789  1 0.04 




 74 2.65 (1.03, 
6.83) 
 
         
Length of 
hospital stay (*) 
Negative 802 5 [3, 9]   1 <0.001 802  1 0.02 




 74 1.20 (1.03, 
1.40) 
 
         
Pancreatic 
Necrosis 
Negative 727 104 
(14.3%) 
  1 0.02 727  1 0.88 
(suspected or 
+ve) 




 76 0.94 (0.46, 
1.95) 
 




Negative 725 169 
(23.3%) 
  1 <0.001 725  1 0.02 
(suspected or 
+ve) 




 76 2.14 (1.16, 
3.96) 
 
         
Pseudo 
aneurysms 
Negative 725 12 
(1.5%) 
  1 0.89 725  1 0.34 
(suspected or 
+ve) 




 76 0.33 (0.03, 
3.24) 
 
         
PL fistula Negative 725 4 
(0.8%) 
 (+) 725  (+) 
(suspected or 
+ve) 
Positive 75 0 
(0.0%) 
  75   
         
Enteric fistula Negative 724 8 
(1.1%) 
 (+) 725  (+) 
(suspected or 
+ve) 
Positive 102 0 
(0.0%) 
  75   
         
Pancreatic 
ascites 
Negative 726 79 
(10.9%) 
  1 0.58 726  1 0.64 
(suspected or 
+ve) 




 76 0.81 (0.33, 
1.97) 
 
         
Portal vein 
thrombus 
Negative 722 28 
(3.9%) 
  1 0.80 722  1 0.19 
(suspected or 
+ve) 




 75 0.33 (0.06, 
1.73) 
 
         
Any local  Negative 722 219 
(30.3%) 
  1 <0.001 722  1 0.11 
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 75 1.65 (0.89, 
3.08) 
 
         
Persistent 
Organ failure 
Negative 798 55 
(6.9%) 
  1 <0.001 798  1   
0.004 




 111 3.42 (1.47, 
7.94) 
 
         
(~) Adjusted for: age, sex, smoking status, alcohol aetiology, idiopathic aetiology, unknown aetiology, other 
aetiology, ECOG, Atlanta classification 
(*) Summary statistics are: Median [p75-p25]. Group differences reported as: Ratio (95% CI) 
(+) Insufficient occurrences to enable a formal group comparison 
(#) Defined as any of: Collection, Pseudoaneurysm, Pancreatic Pleural Fistula, Enteric Fistula, Pancreatic Ascites, 
or Portal Vein Thrombus 
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Supplementary file 6: Comparison of outcomes between unconfirmed SARS-CoV-2 Positive and Negative patients 
 
Outcome COVID  Unadjusted Analysis (**) Adjusted Analysis (~) (***) 
 status N n (%) OR (95% CI) P-value N OR (95% CI) P-value 
         
ICU admission Negative 545 82 (3.3%)   1 <0.001 545  1 0.05 
 Positive 28 8 (28.6%) 33.7 (6.98, 163)  28 15.6 (0.96, 252)  
         
30-day mortality Negative 539 7 (1.3%)    1 0.01 539  1 0.38 
 Positive 28 3 (10.7%) 15.6 (1.88, 130)  28 3.13 (0.25, 39.1)  
         
Length of hospital stay 
(*) 
Negative 539 4 [2, 7]   1 <0.001 539  1 <0.001 
 Positive 27 13 [6, 19] 2.51 (1.94, 3.25)  27 1.71 (1.33, 2.20)  
         
Necrosis Negative 461 41 (8.9%)   1 0.11 461  1 0.15 
(suspected or +ve) Positive 27 5 (18.5%) 2.35 (0.83, 6.67)  27 0.38 (0.10, 1.42)  
         
Collections Negative 465 84 (18.1%)   1   0.007 465  1 0.85 
(suspected or +ve) Positive 27 11 (40.7%) 3.47 (1.41, 8.51)  27 0.90 (0.31, 2.67)  
         
Pseudo aneurysms Negative 460 1 (0.2%)  (+) 460  (+) 
(suspected or +ve) Positive 76 0 (0.0%)   27   
         
PL fistula Negative 463 6 (1.3%)  (+) 463  (+) 
(suspected or +ve) Positive 27 0 (0.0%)   27   
         
Enteric fistula Negative 461 1 (0.2%)  (+) 461  (+) 
(suspected or +ve) Positive 27 2 (7.4%)   27   
         
Pancreatic ascites Negative 461 7 (1.5%)   1 <0.001 461  (+) 
(suspected or +ve) Positive 27 5 (18.5%) 15.3 (3.32, 70.5)  27   
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Portal vein thrombus Negative 458 28 (1.5%)   1 0.39 458  1 0.47 
(suspected or +ve) Positive 26 1 (3.9%) 2.57 (0.30, 21.8)  26 0.38 (0.03, 5.27)  
         
Any local  Negative 458 219 (19.4%)   1 0.01 458  1 0.83 
complication (#) Positive 26 11 (42.3%) 3.31 (1.32, 8.28)  26 1.13 (0.38, 3.41)  
         
Persistent organ failure Negative 540 18 (3.3%)   1 <0.001 540  1 0.79 
 Positive 33 10 (30.3%) 11.7 (4.13, 33.0)  33 1.23 (0.27, 5.64)  
         
(~) Adjusted for: age, sex, smoking status, alcohol aetiology, idiopathic aetiology, unknown aetiology, other aetiology, ECOG, Atlanta classification 
(*) Summary statistics are: Median [p25-p75]. Group differences reported as: Ratio (95% CI) 
(+) Insufficient occurrences to enable a formal group comparison 
(#) Defined as any of: Collection, Pseudoaneurysm, Pancreatic Pleural Fistula, Enteric Fistula, Pancreatic Ascites, or Portal Vein Thrombus 
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